A single-blind, randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules in adolescents
Latest Information Update: 13 May 2024
At a glance
- Drugs NVX CoV 2373 (Primary) ; Tozinameran (Primary) ; Matrix-M1 Adjuvant; Meningococcal vaccine group B
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms Com-COV3
- 09 May 2024 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.
- 16 Jun 2023 Results (N=148) published in the Journal of Infection.
- 09 Jun 2023 Planned End Date changed from 30 Sep 2023 to 31 Mar 2024.